Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab plus docetaxel versus placebo plus docetaxel in previously treated stage IV non-small cell lung cancer
NL-OMON38024Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Ramucirumab + docetaxel with Placebo + docetaxel (2 arms). Primary endpoint: Overall survival. Started Mar 2011; status: active, not recruiting.
02
Drugs
ramucirumabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON38024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38024.